The pre-ablation triglyceride-glucose index predicts late recurrence of atrial fibrillation after radiofrequency ablation in non-diabetic adults

Qinghui Tang, Xiao-Gang Guo, Qi Sun and Jian Ma*

Abstract

Background: Current prognostic risk scoring systems and biomarkers are routinely used as non-invasive methods for assessing late recurrence of atrial fibrillation (AF) in patients who have undergone radiofrequency catheter ablation (RFCA). This study aimed to investigate the predictive value of the triglyceride-glucose (TyG) index for late AF recurrence after RFCA in non-diabetic patients.

Methods: In total, 275 patients with AF who underwent RFCA at the Fuwai hospital (Beijing, China) between January 2016 and December 2018 were enrolled in this study. During follow up, patients were divided into late and non-late AF recurrence groups, based on whether they had experienced late AF recurrence determined by electrocardiography (ECG) examine or 48 h Holter monitoring. The TyG index was calculated using the following equation: ln [fasting triglycerides [mg/dL] × fasting glucose [mg/dL]/2].

Results: During a median follow-up of 26.1 months, late AF recurrence event rates significantly increased in the highest TyG index tertile group (tertile 3) compared to the lowest group (tertile 1) (54% versus 12%, respectively; \( p < 0.001 \)). The mean TyG index was higher in the late AF recurrence group compared to the non-late AF recurrence group (9.42 ± 0.6 versus 8.68 ± 0.7, respectively; \( p < 0.001 \)). On multivariate Cox regression analysis, the pre-ablation TyG index was an independent risk factor for late recurrence of AF after RFCA (hazard ratio [HR] 2.015 [95% confidence interval (CI): 1.408–4.117]; \( p = 0.009 \)). Receiver operating characteristic (ROC) curve analysis revealed that TyG index was a significant predictor of late AF recurrence after RFCA, with an area under the ROC curve (AUC) of 0.737 (95% CI: 0.657–0.816; \( p < 0.001 \)). In addition, the AUC of left atrial diameter (LAD) was 0.780 (95% CI: 0.703–0.857, \( p < 0.001 \)). Finally, the TyG index positively correlated with LAD (\( r = 0.133, p = 0.027 \)), high sensitivity C-reactive protein (\( r = 0.132, p = 0.028 \)) and N-terminal pro B-type natriuretic peptide (\( r = 0.291, p < 0.001 \)) levels.

Conclusions: An elevated pre-ablation TyG index was associated with an increased risk of late AF recurrence after RFCA in non-diabetic patients. The TyG index may be potentially useful as a novel biomarker for the risk stratification of late AF recurrence in non-diabetic patients.

Keywords: Atrial fibrillation, Triglyceride-glucose index, Biomarkers, Predictors of rhythm outcome, Catheter ablation

*Correspondence: majian_fuwai@126.com

Arrhythmia Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Bei Li Shi Road, Xicheng District, Beijing 100037, China

Background

Atrial fibrillation (AF) is an extremely costly public health issue [1]. Worldwide, radiofrequency catheter ablation (RFCA) is the gold standard therapy for
drug-refractory AF [2, 3]. Nevertheless, the long-term AF-free survival period without atrial arrhythmia recurrence remains unsatisfactory, with a reported late AF recurrence rate of up to 30–50% after first pulmonary vein (PV) isolation [4, 5]. Because of the high recurrence rates after RFCA, it is crucial to investigate the clinical risk variables that influence the successful maintenance of sinus rhythm in patients with AF after RFCA [6]. The treatment of patients with recurrent AF after RFCA is challenging [4, 7, 8]. Moreover, among patients with a high risk of post-ablation AF recurrence or with multiple atrial structural remodeling, the cost-effectiveness of RFCA is low [7, 8]. Although several scoring systems, such as the APPLE [Age > 65 years, Persistent AF, impaired eGFR (< 60 ml/min/1.73 m^2), Left atrial diameter ≥ 43 mm, Left ventricular ejection fraction < 50%] [9], CHA2DS2-VASc [congestive heart failure, hypertension, age ≥ 75, diabetes, stroke, vascular disease, age 65 to 74 and sex category] [10], and DR-FLASH score [based on Diabetes mellitus, Renal dysfunction, Persistent AF type, LA diameter > 45 mm, Age > 65 years, Female Sex, and Hypertension] [11] have been proposed to predict late AF recurrence after RFCA, there is no clear consensus regarding a risk scoring system or biomarkers predicting rhythm outcome(s) after RFCA [9–11].

Experimental and clinical findings have revealed that abnormal glucose metabolism and insulin resistance (IR) are involved in atrial electrical and structural remodeling processes and AF development [12, 13]. The triglyceride glucose index (TyG index), calculated using fasting blood glucose and triglyceride (TG) levels, is considered to be a reliable index of IR in clinical practice [13, 14]. IR is a pathological state in which cells or tissues cannot respond normally to insulin, and is characterized by increased body weight, hyperglycemia, dyslipidemia, and elevated blood pressure [15, 16]. Cardiometabolic syndrome and IR are also common among non-diabetic patients and are associated with epicardial fat deposition and vulnerability to AF [12, 17, 18]. IR can induce AF by increasing left atrial (LA) volume or impairing left ventricular diastolic function [18]. However, the prognostic value of the TyG index in patients with late AF recurrence after RFCA remains controversial. This study aimed to validate the TyG index for predicting the rhythm outcome of non-diabetic AF patients who underwent RFCA.

Methods
Study population
This retrospective study enrolled 380 consecutive non-diabetic patients who underwent first-time radiofrequency catheter ablation for AF between January 2016 and December 2018 at Fuwai Hospital (Beijing, China). Patients with AF episodes lasting > 7 days were defined as having persistent AF, and those whose episodes terminated spontaneously within 7 days were defined as having paroxysmal AF. Long-standing persistent AF was defined as persistent AF episodes lasting > 12 months [1]. Obesity was defined as a body mass index (BMI) > 28 kg/m^2 according to the criteria recommended by the National Health Commission in China [19]. Patients with secondary AF (e.g., related to infection, heart surgery, or hyperthyroidism); acute coronary syndrome requiring interventional management; ischemic cardiomyopathy; contraindications to anticoagulation; decompensated heart failure (baseline NYHA classification of class III-IV); left atrial thrombosis, moderate to severe valvular diseases, any taking anti-diabetic or anti-hyperlipidemic agents at baseline and pregnancy, were excluded. The study was approved by the Ethics Committee of Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, and Peking Union Medical College, and was performed in accordance with the Helsinki Declaration. Written informed consent was obtained from all patients.

Risk scoring system
As described above, the APPLE score was evaluated based on 1 point for age > 65 years, persistent AF type, impaired estimated glomerular filtration rate (< 60 ml/min/1.73 m^2), LA diameter > 43 mm, left ventricular ejection fraction < 50%; it ranged from 0 to 5 points, and was assessed before the procedure [9]. The DR-FLASH score was assessed based on 1 point for each of the following parameters: diabetes mellitus, renal dysfunction, LA diameter > 45 mm, persistent AF type, age > 65 years, female sex, and hypertension, and ranged from 0 to 7 points [11]. The CHA2DS2-VASc, APPLE, and DR-FLASH scores were calculated for each patient before AF ablation.

Blood sample collection and processing
Before ablation, fasting blood samples were collected from all patients within 24 h of admission. Serum blood biomarkers (fasting plasma glucose and lipid parameters, including total cholesterol, TG, low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C)) were assessed using standard laboratory techniques at Fuwai Hospital. The TyG index was calculated using the following equation: ln [fasting TG [mg/dL] × fasting glucose [mg/dL]/2].

Electrophysiological study and catheter ablation
Radiofrequency catheter ablation was performed under deep sedation; electrocardiography and oxygen saturation were monitored continuously during the procedure.
LA access was established under X-ray fluoroscopic guidance using double trans-septal puncture. After assessment of the left atrium, a Lasso catheter (Biosense Webster, Diamond Bar, CA, USA) and a 3.5-mm-tip ablation catheter were advanced into left atrium using 8 Fr SL1 trans-septal sheaths (St. Jude Medical Inc., St. Paul, MN, USA). After trans-septal access, a 100 UL/kg bolus of heparin was administered intravenously to maintain an activated clotting time of 300–350 s during the ablation procedure. Three-dimensional electroanatomic mapping of the left atrium was performed using the CARTO 3 system (CARTO, Biosense Webster Inc., Diamond Bar, CA, USA) and the point-by-point method. The PV ostium was identified by selective venography and tagged on the CARTO 3 electroanatomic map. A Lasso catheter was placed approximately 0.5 cm within the PV ostium for real-time monitoring of PV isolation. A contact force of 10–20 g was applied to each ablation point. RFCA energy was delivered at a power setting of 25–35 W with a maximal temperature of 43 °C for at least 30 s for each ablation point. During ablation, the infusion rate was 17–25 mL/min. The inter-lesion ablation point distance for PV isolation was mainly based on local electrogram mapping at the operator’s discretion. PV isolation was defined as PV entrance and exit block confirmed 30 min after the initial isolation with intravenous adenosine to examine acute PV reconnection. PV isolation was the only target and no additional ablation lines were performed. If non-PV focal triggers were documented, then they were ablated using an irrigated contact force RF catheter. If AF persisted after PV isolation, cardioversion was performed. If a common-type atrial flutter was documented, cavotricuspid isthmus linear ablation was performed to achieve bidirectional block.

**Post-procedural management**

Transthoracic echocardiography was performed to exclude pericardial effusion after RFCA. Oral anticoagulants therapy was initiated the day after RFCA. Based on individual CHA2DS2-VASc scores, patients with AF continued to take oral anticoagulants for at least two months according to European Society of Cardiology Guidelines [1]. All patients with persistent AF continued to take amiodarone for three months after RFCA to maintain sinus rhythm and visited the doctors to monitor the side effects of the drug. For paroxysmal AF, any class I or III antiarrhythmic drug would be avoided if patients were free from AF recurrence during the three-month blanking period. In patients with AF recurrence, rate control with β-receptor blockers would first be considered, followed by propafenone as a second-line treatment, if β-receptor blockers did not alleviate the symptoms of discomfort.

All class I or III antiarrhythmic drugs, if administered, were stopped at the end of the blank period.

**Follow-up**

All patients were scheduled for routine outpatient follow-up visits in our hospital at 1-, 3- and 12-months of the 1st year post-ablation, and every 12 months thereafter. Additionally, all patients were advised to receive 12-lead electrocardiography (ECG) or a 48-h Holter examination every month at their local hospital, and an additional 48-h Holter examination if prompted by recurrence of arrhythmia-related symptoms. Outpatient follow-up visits included history taking, physical examination, 12-lead ECG or 48 h-Holter monitoring, and echocardiography. Telephone interviews were conducted to screen for arrhythmia-related symptoms (chest discomfort, palpitations, fatigue, and dizziness). 12-lead ECG or 48-h Holter recording data were sent to the indicated electronic health record system. Early AF recurrence was defined as atrial arrhythmia recurrence within three-month blanking period. Late AF recurrence was defined as AF, atrial flutter, or atrial tachycardia lasting > 30 s recorded by any type of ECG or Holter monitoring after a three-month blanking period. The “AF-free” period was defined as no recurrence of atrial arrhythmia without antiarrhythmic drug use.

**Statistical analysis**

Data distribution in this study was assessed using the Kolmogorov–Smirnov criterion. Continuous variables are expressed as mean ± standard deviation (SD) if normally distributed. Otherwise, they were expressed as medians (interquartile range). The study population was stratified into three tertiles according to the value of pre-ablation TyG index (tertile 1: 6.80 < TyG index < 8.67; tertile 2: TyG index: 8.68–9.37; and tertile 3: TyG index ≥ 9.38). Comparisons of two continuous variables with normal distribution in the study were performed using the independent samples Student’s t-test. Categorical variables are expressed as frequencies and percentages, and were compared using chi-squared test or Fisher’s exact test. Non-parametric variables were compared using the Wilcoxon signed-rank test. Analysis of ANOVA test was used to compare TyG index according to the APPLE, DR-FLASH and CHA2DS2-VASc scores. Univariate and multivariate regression analyses using the backward likelihood ratio method were used to determine the risk predictors of AF recurrence. The covariables in the multivariate Cox regression analysis were mainly selected for the following reasons: the variables were statistically significant in the univariate analysis, or the variables were known to be related to cardiovascular events and thus may serve as potential confounders. Correlation analyses were performed using Spearman’s rank test. Receiver operating
characteristic (ROC) curve analysis was used to assess the predictive value of clinical factors for late AF recurrence and to identify the optimal cut-off value using Youden’s index. Kaplan–Meier survival curves were constructed to evaluate the incidence rate of late AF recurrence in each group, according to tertiles of TyG index. All data were analyzed using SPSS version 25.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism version 5.0 (GraphPad Inc, San Diego, CA, USA). Differences were considered statistically significant at a two-tailed P < 0.05.

Results

Patients population
Among 380 consecutive non-diabetic patients with AF who underwent radiofrequency ablation, 65 patients who met the major exclusion criteria and 40 patients lost to follow-up were excluded (Fig. 1). Consequently, a total of 275 AF patients (29.1% persistent AF and 70.9% paroxysmal AF) were entered into the analysis. The baseline demographic characteristics, demographical laboratory data, and procedural details of both cohorts are summarized in Table 1. The mean patient age was 57.32 ± 9.57 years, and 69.4% were male. After a median follow-up time of 26.1 months, late recurrence of AF was observed in 70 patients (25.5%). We observed late AF recurrence in 24 patients with persistent AF and 46 patients with paroxysmal AF. As was shown in Table 1, patients with late AF recurrence exhibited larger LA diameter (LAD) (42.4 ± 4.6 versus 37.7 ± 4.1 mm; p = 0.001), longer AF duration (79.43 ± 65.7 versus 60.20 ± 58.27 months; p = 0.04), older age (64.38 ± 8.04 versus 55.07 ± 8.93 years; p < 0.001), higher number of patients with long-standing persistent AF (21.4% versus 8.3%, p = 0.010), more patients with early AF recurrence (70% versus 12.7%; p = 0.001), more patients with hypertension (62.8% versus 46.3%; p = 0.02), a higher prevalence of amiodarone treatment (54.3% versus 17.6%; p = 0.01), higher CHA2DS2-VASc score (p = 0.02), as well as higher APPLE (p = 0.01) and DR-FLASH (p = 0.01) scores, compared to patients without late AF recurrence (Table 1). Moreover, the mean value of the TyG index (9.42 ± 0.6 versus 8.68 ± 0.70; p < 0.001), high sensitivity C-reactive protein (hs-CRP) (p < 0.001), and N-terminal pro B-type natriuretic peptide (NT-proBNP) (483 ± 411 versus 237 ± 205 pg/mL; p = 0.005) were significantly greater in patients with late AF recurrence compared to those without late AF recurrence (Table 1). Furthermore, the patients were stratified into three groups according to the value of pre-ablation TyG, as described above, and subgroup analysis showed that patients in T3 group (tertile 3) had a higher rate of late AF recurrence than those in T1 group (tertile 1) (54% versus 12%, p < 0.001) (Fig. 2). Likewise, patients with a higher TyG index (tertile 3) tended to be older (60.6 ± 10.4 versus 55.1 ± 7.5 years; p = 0.001), had elevated BMI (26.3 ± 3.1 versus 25.2 ± 2.0 kg/m²; p = 0.027), enlarged LAD (41.9 ± 4.8 versus 38.1 ± 4.7 mm; p = 0.035), higher hs-CRP level (4.8 ± 4.9 versus 2.4 ± 1.6 mg/L; p = 0.001), higher NT-proBNP level (368.2 ± 379.0 versus 245.7 ± 282.7 pg/mL; p = 0.001), higher APPLE score (p = 0.01), as well as higher DR-FLASH (p = 0.01) and CHA2DS2-VASc (p = 0.025) scores, compared to those in the first tertile (tertile 1) (Table 2).

Fig. 1 The flow chart of the present study
| Parameters                              | Overall population (n = 275) | Late AF recurrence (+) (n = 70) | Late AF recurrence (−) (n = 205) | P-value |
|----------------------------------------|------------------------------|---------------------------------|----------------------------------|---------|
| Age, years (SD)                        | 57.32 ± 9.57                | 64.38 ± 8.04                    | 55.07 ± 8.93                     | p < 0.001|
| Male, sex, n (%)                       | 191 (69.4%)                 | 53 (75.7%)                      | 138 (67.3%)                      | p = 0.092|
| Paroxysmal AF, n (%)                   | 195 (70.9%)                 | 46 (65.7%)                      | 149 (72.7%)                      | p = 0.080|
| Persistent AF, n (%)                   | 80 (29.1%)                  | 24 (34.3%)                      | 56 (27.3%)                       | p = 0.030|
| Long-standing Pers AF, n (%)           | 32 (11.6%)                  | 15 (21.4%)                      | 17 (8.3%)                        | p = 0.010|
| AF duration, months (SD)               | 63.03 ± 60.25               | 79.43 ± 65.7                    | 60.20 ± 58.27                    | p = 0.040|
| BMI, kg/m²                              | 25.7 ± 2.9                  | 25.9 ± 2.6                      | 25.4 ± 3.0                       | p = 0.144|
| CAD history, n (%)                     | 36 (13.1%)                  | 11 (15.7%)                      | 25 (12.2%)                       | p = 0.063|
| Hypertension, n (%)                    | 37 (13.5%)                  | 11 (15.7%)                      | 26 (12.7%)                       | p = 0.515|
| Previous stroke/TIA, n (%)             | 139 (50.5%)                 | 44 (62.8%)                      | 95 (46.3%)                       | p = 0.020|
| Amiodarone use, n (%)                  | 74 (26.9%)                  | 38 (54.3%)                      | 36 (17.6%)                       | p = 0.010|
| Alcohol intake, n (%)                  | 62 (22.5%)                  | 19 (27.1%)                      | 43 (21.0%)                       | p = 0.090|
| Current smoking, n (%)                 | 79 (28.7%)                  | 20 (28.6%)                      | 59 (28.8%)                       | p = 0.345|
| Echocardiography                       |                              |                                 |                                  |         |
| LA diameter (AP), mm                   | 38.4 ± 4.68                 | 42.4 ± 4.60                     | 37.7 ± 4.10                      | p = 0.001|
| LVEF (%)                               | 63.90 ± 5.2                 | 63.66 ± 5.0                     | 64.20 ± 5.2                      | p = 0.907|
| Laboratory findings                    |                              |                                 |                                  |         |
| NT-proBNP, pg/mL                       | 271 ± 254                   | 483 ± 411                       | 237 ± 205                        | p = 0.005|
| hs-CRP, mg/L                           | 2.29 (1.57–3.15)            | 3.58 (1.75–5.27)                | 2.15 (1.47–2.90)                 | p < 0.001|
| Uric acid, μmol/L                      | 340.8 ± 82.8                | 349.2 ± 79.6                    | 339 ± 81.5                       | p = 0.356|
| Hcy, μmol/L                            | 17.8 ± 2.3                  | 18.3 ± 2.5                      | 16.9 ± 1.9                       | p = 0.068|
| FPG (mmol/L)                           | 5.5 (5.1–6.2)               | 6.0 (5.4–6.9)                   | 5.1 (4.7–5.8)                    | p = 0.008|
| HbA1c, %                               | 5.1 ± 0.2                   | 5.1 ± 0.3                       | 5.1 ± 0.1                        | p = 0.352|
| TC, mmol/L                             | 4.33 ± 1.03                 | 4.35 ± 1.05                     | 4.31 ± 1.01                      | p = 0.125|
| HDL-C, mmol/L                          | 3.13 ± 1.05                 | 3.15 ± 1.09                     | 3.11 ± 1.03                      | p = 0.218|
| LDL-C, mmol/L                          | 2.31 ± 0.43                 | 2.50 ± 0.32                     | 2.20 ± 0.50                      | p = 0.108|
| HDL-C, mmol/L                          | 1.21 ± 0.30                 | 1.23 ± 0.40                     | 1.18 ± 0.22                      | p = 0.125|
| TG, mmol/L                             | 1.78 (1.32–2.29)            | 2.65 (2.09–3.52)                | 1.65 (1.15–2.18)                 | p = 0.006|
| Creatinine, μmol/L                     | 79.5 ± 15.7                 | 81.7 ± 15.0                     | 78.7 ± 15.9                      | P = 0.533|
| TyG index                              | 8.87 ± 0.8                  | 9.42 ± 0.6                      | 8.68 ± 0.70                      | p < 0.001|
| Clinical scoring point                 |                              |                                 |                                  |         |
| EHRA score                             | 2 (1–3)                     | 2 (1–3)                         | 2 (1–3)                          | p = 0.236|
| CHA2DS2-VASc score                     | 1 (0–2)                     | 2 (1–3)                         | 1 (0–2)                          | p = 0.020|
| HAS-BLED score                         | 1 (0–1)                     | 1 (0–1)                         | 1 (0–1)                          | p = 0.219|
| DR-FLASH score                         | 2 (1–2)                     | 3 (2–4)                         | 1 (1–2)                          | p = 0.010|
| APPLE score                            | 1 (0–1)                     | 2 (1–3)                         | 1 (0–1)                          | p = 0.010|
| Early recurrence                       | 75 (27%)                    | 49 (70%)                        | 26 (12.7%)                       | p < 0.001|

Data were expressed as mean ± SD, median with 25th and 75th percentile or n (%).

AF: atrial fibrillation; BMI: body mass index; NT-proBNP: N-terminal B-type natriuretic peptide; Hcy: homocysteine; Hba1c: glycosylated hemoglobin; CAD: coronary artery disease; SAS: sleep apnea syndrome; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; FPG: fasting plasma glucose; TyG index: triglyceride-glucose index; hs-CRP: high-sensitivity C-reactive protein; LVEF: left ventricular ejection fraction; LAD: left atrial diameter; TIA: transient ischemic attack; Early recurrence: atrial arrhythmia recurrence within three-month blanking period; EHRA score: EHRA symptom score suggested by European Heart Rhythm Association; HAS-BLED score: hypertension, abnormal liver/renal function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly.
Comparison of TyG index

As was shown in Fig. 3, the TyG index was significantly higher in patients with late AF recurrence compared to patients without late AF recurrence (medians: 9.55 vs 8.75; \(p < 0.001\)). Moreover, the TyG index was elevated in patients with LAD > 40 mm, compared to patients with LAD < 40 mm (medians: 9.26 vs 8.95; \(p = 0.010\)). Similarly, the TyG index was elevated in the obese patients compared to non-obese patients (medians: 9.25 vs 8.97; \(p = 0.011\)).

Prediction of late AF recurrence using clinical variables

Univariate Cox proportional hazards regression analysis showed that older age (> 65 years), LA diameter, AF type (persistent AF), AF history > 5 years, early AF recurrence, TyG index, LDL-C level, hs-CRP level, NT-proBNP level, CHA2DS2-VASc score, APPLE score and DR-FLASH score, were significantly associated with late AF recurrence (all of the variables, \(p < 0.05\)) (Table 3). Multivariate Cox regression analysis confirmed that TyG index (HR: 2.015, 95% CI: 1.408–4.117, \(p = 0.009\)), LA diameter (HR: 3.514, 95% CI: 2.083–5.929, \(p = 0.001\)), older age (> 65 years) (HR: 1.165, 95% CI: 1.013–1.340, \(p = 0.032\)), early AF recurrence (HR: 1.093, 95% CI: 1.001–1.193, \(p = 0.042\)), APPLE score (HR: 1.697, 95% CI: 1.116–2.581, \(p = 0.010\)) and DR-FLASH score (HR: 1.387, 95% CI: 1.052–1.830, \(p = 0.021\)), were significantly associated with late AF recurrence (Fig. 2).

Table 2  Clinical characteristics of AF patients according to tertiles of TyG index

| Parameters                   | Tertile 1 n = 131 | Tertile 2 n = 77 | Tertile 3 n = 67 | P value |
|------------------------------|------------------|-----------------|-----------------|---------|
| Age, years (SD)              | 55.1 ± 7.5       | 57.1 ± 10.6     | 60.6 ± 10.4     | 0.001   |
| Male, sex, n (%)             | 85 (64.8%)       | 55 (71.4%)      | 51 (76.1%)      | 0.395   |
| Paroxysmal AF, n (%)         | 91 (69.5%)       | 56 (72.7%)      | 48 (71.6%)      | 0.654   |
| AF duration, months (SD)     | 62.3 ± 60.4      | 67.9 ± 50.9     | 69.8 ± 62.8     | 0.168   |
| BMI, kg/m²                   | 25.2 ± 2.0       | 25.7 ± 3.2      | 26.3 ± 3.1      | 0.027   |
| CAD history, n (%)           | 15 (11.4%)       | 12 (15.6%)      | 9 (13.4%)       | 0.096   |
| Hypertension, n (%)          | 70 (53.4%)       | 41 (53.2%)      | 28 (41.8%)      | 0.068   |
| SAS history, n (%)           | 16 (12.2%)       | 11 (14.3%)      | 10 (14.9%)      | 0.218   |
| Previous stroke/TIA, n (%)   | 6 (4.6%)         | 4 (5.2%)        | 3 (4.5%)        | 0.452   |
| Echocardiography             |                 |                 |                 |         |
| LAD, mm                      | 38.1 ± 4.7       | 39.0 ± 4.5      | 41.9 ± 4.8      | 0.035   |
| LVEF (%)                     | 64.0 ± 5.3       | 63.8 ± 5.1      | 64.5 ± 5.7      | 0.674   |
| Biochemistry                 |                 |                 |                 |         |
| NT-proBNP, pg/mL             | 245.7 ± 282.7    | 275.3 ± 325.0   | 368.2 ± 379.0   | 0.001   |
| hs-CRP, mg/L                 | 2.4 ± 1.6        | 3.5 ± 3.8       | 4.3 ± 4.9       | 0.001   |
| Uric acid, umol/L            | 332.5 ± 80.5     | 338.3 ± 81.2    | 346.5 ± 79.5    | 0.352   |
| Hcy, μmol/L                  | 16.2 ± 1.5       | 18.2 ± 2.1      | 18.6 ± 2.2      | 0.115   |
| Risk scoring system          |                 |                 |                 |         |
| CHA2DS2-VASc score           | 1 (1–2)          | 1 (1–2)         | 2 (1–3)         | 0.025   |
| APPLE score                  | 1 (0–1)          | 1 (1–2)         | 2 (1–3)         | 0.010   |
| DR-FLASH score               | 1 (0–2)          | 2 (1–2)         | 3 (2–4)         | 0.010   |

Data were expressed as mean ± SD, median with 25th and 75th percentile or n (%)

AF atrial fibrillation, BMI body mass index, NT-proBNP N-terminal B-type natriuretic peptide, Hcy homocysteine, CAD coronary artery disease, SAS sleep apnea syndrome, TyG index triglyceride–glucose index, hs-CRP high-sensitivity C-reactive protein, LVEF left ventricular ejection fraction, LAD left atrial diameter, TIA transient ischemic attack
recurrence (Table 3). According to the ROC curve analysis, the TyG index was a significant predictor of late AF recurrence (AUC = 0.737, 95% CI: 0.657–0.816; p < 0.001). Additionally, LAD, CHA2DS2-VASc score, APPLE score, and DR-FLASH score were also significant predictors of late AF recurrence after RFCA (LAD: AUC = 0.780, 95% CI: 0.703–0.857, p < 0.001; APPLE score: AUC = 0.752, 95% CI: 0.675–0.830, p < 0.001; DR-FLASH score: AUC = 0.797, 95% CI: 0.723–0.871, p < 0.001; CHA2DS2-VASc score: AUC = 0.624, 95% CI: 0.533–0.715, p = 0.006, respectively) (Fig. 4). The cutoff value for the TyG index was 9.24 based on the ROC analysis, and the corresponding sensitivity and specificity were 89.1% and 57.3%, respectively. Kaplan–Meier analyses

Table 3: Univariate and multivariate Cox proportional hazards regression analysis of late AF recurrence

| Variables                        | Univariate Cox regression | Multivariate Cox regression |
|----------------------------------|---------------------------|----------------------------|
|                                  | HR (95%CI)                | p                          | HR (95%CI)            | p  |
| Clinical parameters              |                           |                            |                           |    |
| Age > 65 years                   | 1.693 (1.238–2.316)       | < 0.001                    | 1.165 (1.013–1.340)     | 0.032 |
| Male gender                      | 0.683 (0.301–1.552)       | 0.360                      |                            |    |
| Hypertension                     | 1.105 (0.581–2.196)       | 0.074                      |                            |    |
| BMI > 28 kg/m²                   | 1.251 (0.715–1.215)       | 0.075                      |                            |    |
| hs-CRP                           | 1.072 (1.028–1.118)       | 0.001                      | 1.135 (0.921–1.325)      | 0.065 |
| NT-proBNP, pg/mL                 | 1.015 (1.007–1.025)       | 0.001                      | 1.038 (0.881–2.705)      | 0.121 |
| Uric acid, μmol/L                | 1.323 (0.912–1.92)        | 0.733                      |                            |    |
| LDL-C, mmol/L                    | 2.167 (1.165–4.030)       | 0.020                      | 1.938 (0.644–5.838)      | 0.239 |
| HCY, μmol/L                      | 1.702 (0.977–2.965)       | 0.061                      |                            |    |
| Creatinine, μmol/L               | 1.013 (0.996–1.030)       | 0.135                      |                            |    |
| TyG index                        | 1.512 (1.220–1.872)       | 0.005                      | 2.015 (1.408–4.117)      | 0.009 |
| Alcohol intake                   | 1.451 (0.744–2.95)        | 0.264                      |                            |    |
| PersAF                           | 1.103 (1.005–1.210)       | 0.040                      | 1.172 (0.635–1.819)      | 0.235 |
| Duration of AF history > 5 years | 1.003 (1.000–1.006)       | 0.029                      | 1.079 (0.642–2.825)      | 0.775 |
| EHRA score                       | 0.938 (0.563–1.563)       | 0.805                      |                            |    |
| CHA2DS2-VASc score               | 1.464 (1.126–1.903)       | 0.003                      | 1.135 (0.977–1.292)      | 0.055 |
| APPLE score                      | 3.479 (2.442–4.957)       | < 0.001                    | 1.697 (1.116–2.581)      | 0.010 |
| DR-FLASH score                   | 2.309 (2.004–2.835)       | < 0.001                    | 1.387 (1.052–1.830)      | 0.021 |
| Echocardiographic parameters     |                           |                            |                           |    |
| LVEF                             | 0.984 (0.937–1.033)       | 0.515                      |                            |    |
| LAD                              | 6.477 (3.943–10.639)      | < 0.001                    | 3.514 (2.083–5.929)      | 0.001 |
| Early AF recurrence              | 2.871 (1.809–4.556)       | < 0.001                    | 1.093 (1.001–1.193)      | 0.042 |

AF: atrial fibrillation, BMI: body mass index, TyG index: triglyceride-glucose index, HCY: homocysteine, NT-proBNP: N-terminal B-type natriuretic peptide, LDL-C: low-density lipoprotein cholesterol, LAD: left atrial diameter, LVEF: left ventricular ejection fraction, Early AF recurrence: AF recurrence during the blanking period, hs-CRP: high-sensitivity C-reactive protein.
revealed that patients in highest tertile of TyG index (T3) presented lower event-free survival, compared to those in the first tertile (p < 0.001 by log-rank test, Fig. 4). In this case, the TyG index may be a reliable predictor for late AF recurrence after RFCA, similar to traditional risk factors, such as old age, LAD, APPLE, and DR-FLASH scores.

Correlations between TyG index and key cardiac variables and blood biomarkers

In Spearman correlation analyses, an elevated TyG index was positively correlated with LAD (r = 0.133, p = 0.027), hs-CRP (r = 0.132, p = 0.028) and NT-proBNP (r = 0.291, p < 0.001) (Fig. 5) in non-diabetic patients. However, the correlation coefficients were low, and studies with larger sample sizes are required to validate our results.

Value of the TyG index according to prognostic risk scoring system

In this study, we found that various prognostic risk scoring systems (APPLE, DR-FLASH and CHA2DS2-VASc scores) were closely associated with late AF recurrence after RFCA. Furthermore, we investigated the TyG index distribution according to those risk scoring systems. We found that the value of TyG index significantly increased as the mentioned scores elevated: (i) APPLE score (median TyG index 9.65 in APPLE score of 4 points versus 8.80 in APPLE score of 0 points; p < 0.001); (ii)
DR-FLASH score: median TyG index 9.52 in DR-FLASH score of 5 points versus 8.70 in DR-FLASH score of 0 points; \( p = 0.001 \); iii) CHA2DS2-VASc score: median TyG index 9.36 in CHA2DS2-VASc score > 3 points versus median 8.89 in CHA2DS2-VASc score of 0 points; \( p = 0.015 \) (Fig. 6).

**Discussion**

In the present study, we assessed the predictive ability of the TyG index to estimate late AF recurrence after RFCA and identified an AUC of 0.737 (95% CI: 0.657–0.816; \( p < 0.001 \)) in non-diabetic patients.

Additionally, we investigated the relationship between the TyG index and LA diameter (LAD), prognostic risk scores, and other key biomarkers. The results revealed that the TyG index levels increased with increasing APPLE, DR-FLASH and CHA2DS2-VASc scores. Moreover, the TyG index was associated with conventional risk factors for AF such as LAD, hs-CRP and NT-proBNP.

IR refers to the inability of peripheral tissues to correctly use endogenous insulin for maintaining glucose homeostasis in the body [15, 16]. IR is associated with LA remodeling and AF development, even before diabetes [17, 18, 20]. IR may predispose patients to AF progression by increasing LA size or impairing left ventricular diastolic function [18, 20, 21]. Patients with type 2 diabetes usually experience IR and pre-diabetes stages, although these stages are usually not diagnosed in non-diabetic adults [12, 20]. Metabolic syndrome and IR are common in adults without diabetes, and risk factors related to the development of AF have also been described [20, 21]. Previous investigations have confirmed the pathological mechanism of dominant hyperglycemia-related atrial remodeling and arrhythmia in animal models of impaired glucose tolerance [22, 23]. In an animal mode of IR, IR was associated with various aspects of LA remodeling, including increased oxidative stress injury [24], elevated expression of hyperphosphorylated calcium related proteins, and atrial interstitial fibrosis [22–24]. IR promotes LA structural remodeling and abnormal intracellular calcium homeostasis [18], resulting in increased susceptibility to AF [17]. Increased oxidative stress and inflammation can lead to IR and impaired insulin secretion [24]. Inflammation, IR, and oxidative stress injury are linked to one another and, consequently, result in atrial electrical remodeling [18, 24], LA fibrosis [18], and LA low-voltage areas (LVAs) [25], which are likely the main constituents of AF pathophysiology [25, 26]. Most components of IR, such as glucose tolerance abnormalities, obesity and abnormal lipid levels, were found to have an additive effect on the risk of AF progression, which has been reported to be related to late recurrence of AF after RFCA [15, 17].

The TyG index has been proposed as a reliable, valid, and reproducible surrogate marker for IR [13, 14]. Although the hyperinsulinemic-euglycemic clamp is considered as the current gold standard biomarker for measuring insulin sensitivity, it is a complicated evaluation method with limited clinical applicability [14, 27]. As an alternative biomarker, the TyG index was calculated using more accessible and less costly biochemical parameters associated with many cardiovascular diseases (CVDs) [27]. In addition, the TyG index is closely associated with in vivo IR measured using a hyperinsulinaemic-euglycemic clamp [13, 14]. Cardiometabolic risk factors such as dyslipidemia, hyperglycemia, central obesity, and hypertension, which are independent risk factors for CVDs, were independently associated with the TyG index [27, 28]. Patients with cardiometabolic disorders or IR may be more susceptible to AF recurrence following RFCA [15, 17]. To date, only a limited number of metabolic profiling studies investigating late AF recurrence have...
been performed. Whether the TyG index is associated with late AF recurrence after RFCA is a topic of intense research interest. In the present study, an elevated pre-ablation TyG index was associated with an increased risk of post-ablation AF recurrence. Additionally, the TyG index was associated with conventional risk factors for AF, such as LAD, hs-CRP and NT-proBNP; however, this needs to be further investigated in larger sample studies.

The CHADS$_2$ [10], CHA$_2$DS$_2$-VASc [10], APPLE [9] and DR-FLASH [11] scores are promising prognostic models for atrial arrhythmia recurrence after RFCA. The CHA$_2$DS$_2$-VASc scoring system has been validated as a risk stratification model for predicting LVAs and poor rhythm outcomes after RFCA [10]. APPLE and DR-FLASH scores were recently verified as predictors of LA fibrosis and LVAs, which are closely associated with AF progression and reflect the severity of the AF stage [9, 11]. A recent study reported that APPLE and DR-FLASH scores were associated with LA remodeling or fibrosis [9, 11, 25]. In the present study, we found that the elevated TyG index significantly increased as the APPLE, DR-FLASH and CHA$_2$DS$_2$-VASc scores increased. This implies that the TyG index may reflect the atrial structural remodeling process and late AF recurrence.

**Limitation**
Firstly, this study was a single-center retrospective cross sectional study. Secondly, 12-lead ECG or 48-h Holter monitoring was used for follow-up in this study but it may be underpowered when 7-day Holter monitoring and even implantable loop recorder were widely used as standard monitor technology. Not all the patients received routine Holter monitoring in this study and further studies with continuous rhythm monitoring during long-term follow-up are needed to confirm our findings. Finally, more than 10% of patients were lost in the follow-up and larger sample observational studies are needed to validate our result.

**Conclusion**
The findings of this study suggest that an elevated TyG index is independently associated with late AF recurrence after RFCA in non-diabetic patients. Large-sample observational studies are warranted to provide conclusive evidence; however, it may be plausible to conclude that the TyG index may be useful as a biomarker for risk stratification and patient selection for AF ablation, among non-diabetic patients.

**Abbreviations**
TyG index: Triglyceride-glucose index; AF: Atrial fibrillation; BMI: Body mass index; CAD: Coronary artery disease; LDL-C: Low-density lipoprotein cholesterol; TG: Triglycerides; FBG: Fasting blood glucose; NT-proBNP: N-terminal pro B-type natriuretic peptide; IR: Insulin resistance; ECG: electrocardiography; hs-CRP: High-sensitivity C-reactive protein; PV: Pulmonary vein; RFCA: Radiofrequency catheter ablation; LA: Left atrial; LAD: Left atrial diameter; LVAs: Low-voltage areas; ROC: Receiver operating characteristic; AUC: Area under the receiver operating characteristic curve.
8. Sotomi Y, Inoue K, Tanaka K, Toyoshima Y, Oka T, Tanaka N, et al. Persistent left atrial remodeling after catheter ablation for non-paroxysmal atrial fibrillation is associated with very late recurrence. J Cardiol. 2015;66(5):370–6.

9. Kornej J, Hindricks G, Shoemaker MB, Husser D, Aya A, Sommer P, et al. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clin Res Cardiol. 2015;104(10):871–6.

10. Letsas KE, Efremidis M, Giannopoulos G, Deftereos S, Lioni L, Korantzopoulos P, et al. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation. Europace. 2014;16(2):202–7.

11. Kosisk J, Dinov B, Kornej J, Acou WJ, Schönauer R, Fiedler L, et al. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. Heart Rhythm. 2015;12(11):2207–12.

12. Böhme LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights. Front Physiol. 2019;10:135.

13. Wei Z, Zhu E, Ren C, Dai J, Li J, Lai Y. Triglyceride-glucose index independently predicts new-onset atrial fibrillation for septic myectomy for hypertrophic obstructive cardiomyopathy beyond the traditional risk factors. Front Cardiovasc Med. 2021;8:692511.

14. Demiro I, Haymana C, Candemir B, Menic C, Yüksel E, Haymana C, Yüksel E, Eser M, et al. Triglyceride-glucose index levels in patients with congenital hypogonadotropic hypogonadism and the relationship with endothelial dysfunction and insulin resistance. Endokrynol Pol. 2021;72(3):232–7.

15. Hijioka N, Kamioka M, Matsumoto Y, Nodera M, Yamada S, Kaneshiro T, et al. Clinical impact of insulin resistance on pulmonary vein isolation outcome in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(4):479–86.

16. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S135–48.

17. Wang Z, Wang YJ, Liu ZY, Li Q, Kong YW, Chen YW, et al. Effect of insulin resistance on recurrence after radiofrequency catheter ablation in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07317-z.

18. Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18(1):125.

19. Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17 Suppl 1:1–36.

20. Lee Y, Cha SJ, Park JH, Shin JH, Lim YH, Park HC, et al. Association between insulin resistance and risk of atrial fibrillation in non-diabetics. Eur J Prev Cardiol. 2020;27(18):1934–41.

21. Fontes JD, Lyassa A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109(1):87–90.

22. Sah SP, Singh B, Choudhary S, Kumar A. Animal models of insulin resistance on recurrence after radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(4):479–86.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.